


CLAIMS

1. A compound of Formula (1):



5 or a pharmaceutically acceptable salt thereof, wherein:

~~wherein V is CR^AR^B;~~

~~— n is 1 or 2;~~

~~— Z is nitrogen atom, carbon atom, or CR^J;~~


~~— t is 1, 2, or 3;~~

10 ~~— the bond (a) accompanied with broken line is single bond or double bond;~~

~~— R^A and R^B are each independent, where each symbol may be independently the same or different when each symbol exists plurally, and are hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₃₋₁₀ cycloalkyl (wherein the alkyl, the alkoxy, and the cycloalkyl moieties may be each independent and optionally substituted with the same or different 1 to 3 halogen atoms);~~

15 ~~— R^{1a}, R^{1b}, R^{1c}, and R^{1d} are each independently hydrogen atom, halogen atom, or C₁₋₆ alkyl optionally substituted with the same or different 1 to 3 halogen atoms;~~

20 Ring Q¹ is a group of the following Formula (2):



(2)

wherein Ring Q^3 is ~~an optionally substituted~~ a 5- or 6-membered aromatic heterocyclic ring;

wherein the 5- or 6-membered aromatic heterocyclic ring is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, NH_2 , OH, OC_{1-6} alkyl, and C_{3-10} cycloalkyl;

wherein each C_{1-6} alkyl substituent of Ring Q^3 is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and OC_{1-6} alkyl;

wherein each NH_2 substituent of Ring Q^3 is optionally and independently substituted with 1 or 2 independently selected C_{1-6} alkyl substituents;

wherein each OC_{1-6} alkyl substituent of Ring Q^3 is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and

wherein each C_{3-10} cycloalkyl substituent of Ring Q^3 is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

W is CR^{CR^D} ;

X is $-CH_2-$;

Y is N;

m is 0;

~~m is 0 or 1;~~


~~X is CR^E or CR^FR^G ;~~

~~Y is nitrogen atom or CR^H ;~~

~~the bond (b) accompanied with broken line is a single bond or double bond; and~~

~~~~~ is the point of attachment to V;

Ring Q<sup>2</sup> is ~~a group of the following~~ Formula (3a) or  
5 Formula (3b):



wherein

~~~~~ is the point of attachment to Z;

each V is independently -CR^AR^B-;

10 Z is C, CR^J, or N;

R^{1a} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

15 R^{1b} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1c} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

20 R^{1d} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{2a} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;

25 wherein the C₁₋₆ alkyl or OC₁₋₆ alkyl of R^{2a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH₂ of R^{2a} is optionally substituted with 1

or 2 independently selected C₁₋₆ alkyl substituents;

R^{2b} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;

5 wherein the C₁₋₆ alkyl or OC₁₋₆ alkyl of R^{2b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH₂ of R^{2b} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents;

10 R^{2c} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;

wherein the C₁₋₆ alkyl or OC₁₋₆ alkyl of R^{2c} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

15 wherein the NH₂ of R^{2c} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents;

R^{2d} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;

20 wherein the C₁₋₆ alkyl or OC₁₋₆ alkyl of R^{2d} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH₂ of R^{2d} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents;

25 each R^A is independently hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein each C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

30 each R^B is independently hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein each C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

R^C is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl,

wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^D is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl,

5 wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^J is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl,

10 wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

bond (a) is a single or double bond;

n is 1 or 2; and t is 2;

with the provisos that:

15 (I) when Ring Q³ is an optionally substituted 5-membered aromatic heterocyclic ring, then R^{2a} is hydrogen, R^{2b} is hydrogen, R^{2c} is hydrogen, and R^{2d} is hydrogen; and

(II) when bond (a) is a double bond, then Z is C~~wherein R^{2a}, R^{2b}, R^{2c}, and R^{2d} are each independently hydrogen atom, halogen atom, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy (wherein the alkyl and the alkoxy moieties may be each independent and optionally substituted with the same or different 1 to 3 halogen atoms), or amino optionally substituted with the same or different 1 or 2 C₁₋₆ alkyl;~~

20

25 ~~— R^C, R^D, R^E, R^F, R^G, R^H, and R^J are each independently hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₃₋₁₀ cycloalkyl (wherein the alkyl, the alkoxy, and the cycloalkyl moieties may be each independent and optionally substituted with the same or different 1 to 3 halogen atoms), provided that when~~

30 ~~R^F and R^G are C₁₋₆ alkyl, then these groups may combine together with the carbon atom to which they attach to form a 3 to 6 membered saturated carbocyclic ring;~~

~~— provided that~~

~~(I) when Ring Q³ is an optionally substituted 5-membered aromatic heterocyclic ring, then R^{2a}, R^{2b}, R^{2c}, and R^{2d} are hydrogen atom;~~

~~(II) when Ring Q³ is an optionally substituted 6-membered aromatic heterocyclic ring, then m is 0;~~

~~(III) when the bond (a) accompanied with broken line is double bond, then Z is carbon atom;~~

~~(IV) when the bond (b) accompanied with broken line is single bond, then X is CR^FRG; and~~

~~(V) when the bond (b) accompanied with broken line is double bond, then X is CR^F, or a pharmaceutically acceptable salt thereof.~~


2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q³ is a 5- or 6-membered aromatic heterocyclic ring; wherein the 5- or 6-membered aromatic heterocyclic ring is optionally substituted with the same or different 1, 2, or to 3 substituents independently groups selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl;
wherein each C₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;
wherein each OC₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and
wherein each C₃₋₁₀ cycloalkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents~~hydrogen atom, halogen atom, cyano, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl (wherein the alkyl and the cycloalkyl moieties may be each~~

~~independent and optionally substituted with the same or different 1 to 3 halogen atoms), and C₁₋₆ alkoxy (wherein the alkoxy moiety may be optionally substituted with the same or different 1 to 3 halogen atoms or 4 to 8 membered saturated heterocyclyl), or a pharmaceutically acceptable salt thereof.~~

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is CH.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is N.

~~5. The compound according to claim 1 or 2, wherein~~
Formula (1) the compound is of Formula (1a):



or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1b} is hydrogen or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1c} is hydrogen or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1d} is hydrogen or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents~~wherein Q¹, Q², V, Z, n, R^{1a}, R^{1b}, R^{1c}, R^{1d}, and the bond (a) accompanied with broken line are as defined in the above, or a pharmaceutically acceptable salt thereof.~~


~~4. The compound according to any one of claims 1 to 3, wherein R^{1a}, R^{1b}, R^{1c}, and R^{1d} are hydrogen atom, or a pharmaceutically acceptable salt thereof.~~

~~5. The compound according to any one of claims 1 to 4, wherein both of R^A and R^B are hydrogen atom, or a pharmaceutically acceptable salt thereof.~~

~~6. The compound according to any one of claims 1 to 5, wherein n is 2, or a pharmaceutically acceptable salt thereof.~~

~~7. The compound according to any one of claims 1 to 6, wherein the bond (a) accompanied with broken line is single bond, or a pharmaceutically acceptable salt thereof.~~

~~8~~6. The compound according to claim 1 ~~or 2~~, wherein the compound is of Formula (1) ~~is represented by the following Formula (1b):~~



(1b)

~~wherein Q¹, Q², and Z are as defined in the above, or a~~

pharmaceutically acceptable salt thereof.





9. ~~The compound according to any one of claims 1 to 8,~~
~~wherein Z is nitrogen atom, or a pharmaceutically~~
 5 ~~acceptable salt thereof.~~

10. ~~The compound according to any one of claims 1 to 8,~~
~~wherein Z is CH, or a pharmaceutically acceptable salt~~
 thereof.

11. ~~The compound according to any one of claims 1 to 10,~~
~~wherein Y is nitrogen atom, or a pharmaceutically~~
~~acceptable salt thereof.~~

12. ~~The compound according to any one of claims 1 to 11,~~
~~wherein the bond (b) accompanied with broken line is single~~
~~bond and X is CH₂, or a pharmaceutically acceptable salt~~
~~thereof.~~

13. ~~The compound according to any one of claims 1 to 12,~~
7. The compound according to claim 1, or a pharmaceutically
acceptable salt thereof, wherein Ring Q1 is Formula (4a),
Formula (4b), Formula (4c), or Formula (4e)~~wherein Ring Q¹~~
~~is any one of the following Formula (4a), (4b), (4c), (4d),~~
 25 ~~(4e), or (4f):~~



wherein:

R^{3a} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6} alkyl;

wherein the C_{1-6} alkyl of R^{3a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

wherein the NH_2 of R^{3a} is optionally substituted with 1 or 2 independently selected C_{1-6} alkyl substituents; and

wherein the OC_{1-6} alkyl of R^{3a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{3b} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6}

6 alkyl;


wherein the C₁₋₆ alkyl of R^{3b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

wherein the NH₂ of R^{3b} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents; and

wherein the OC₁₋₆ alkyl of R^{3b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

 is the point of attachment to V~~wherein R^{3a} and R^{3b} are each independently hydrogen atom, halogen atom, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy (wherein the alkyl and the alkoxy moieties may be each independent and optionally substituted with the same or different 1 to 3 halogen atoms), or amino optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl, or a pharmaceutically acceptable salt thereof.~~

148. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Ring Q¹ is Formula (5a), Formula (5b), Formula (5c), or Formula (5d)~~wherein Ring Q¹ is any one of the following Formula (5a), (5b), (5c), (5d), (5e), (5f), or (5g):~~



wherein R^{4a} is C_{1-6} alkyl or OC_{1-6} alkyl ~~C_{1-6} alkoxy~~,

R^{4b} is hydrogen atom ~~or~~ C_{1-6} alkyl; and


5 ~~~~~ is the point of attachment to V_7 ,

~~R^{4e} and R^{4d} are each independently hydrogen atom or C_{1-6} alkyl, provided that when one of R^{4e} or R^{4d} is hydrogen atom,~~

~~then the other is C₁₋₆ alkyl, or alternatively, R^{4e} and R^{4d} may combine together with the carbon atom to which they attach to form a 3 to 6 membered saturated carbocyclic ring, or a pharmaceutically acceptable salt thereof.~~

5


9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q² is Formula (3a):

10 wherein:

~~~~~ is the point of attachment to Z.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q<sup>2</sup> is Formula (3b):

15



wherein:

~~~~~ is the point of attachment to Z.

20 11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R^{1a} is hydrogen;

R^{1b} is hydrogen;

R^{1c} is hydrogen; and

R^{1d} is hydrogen.

5 12. The compound according to claim 1, or a
pharmaceutically acceptable salt thereof, wherein:

R^{2a} is hydrogen;

R^{2b} is hydrogen;

R^{2c} is hydrogen; and

10 R^{2d} is hydrogen.

13. The compound according to claim 1, or a
pharmaceutically acceptable salt thereof, wherein:

each R^A is independently hydrogen; and

15 each R^B is independently hydrogen.

14. The compound according to claim 1, or a
pharmaceutically acceptable salt thereof, wherein bond (a)
is a single bond.

20

15. The compound according to claim 1, or a
pharmaceutically acceptable salt thereof, wherein n is 2.

25

~~15. The compound according to any one of claims 1 to 14,~~
~~wherein Ring Q² is a group of Formula (3a), or a~~
~~pharmaceutically acceptable salt thereof.~~






30


~~16. The compound according to any one of claims 1 to 14,~~
~~wherein Ring Q² is a group of Formula (3b), or a~~
~~pharmaceutically acceptable salt thereof.~~

~~17. The compound according to any one of claims 1 to 16,~~
~~wherein R^{2a}, R^{2b}, R^{2c}, and R^{2d} are hydrogen atom, or a~~


~~pharmaceutically acceptable salt thereof.~~

~~1816.~~ The compound according to claim 1, wherein the
compound is selected from the group consisting of~~which is~~
 5 ~~represented by any one of the following formulae:~~






, and




,

or a pharmaceutically acceptable salt thereof.


- 5 17. The compound according to claim 1, wherein the compound is represented by any one of the following formulae:



,




,




_____ ,
or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 17, which is
 5 represented by the following formula:



or a pharmaceutically acceptable salt thereof.


19. The compound according to claim 17, which is
 10 represented by the following formula:



or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 17, which is

represented by the following formula:



or a pharmaceutically acceptable salt thereof.

5 ~~1921.~~ A drug comprising a compound according to ~~any one~~
~~of claims 1 to 18,~~ or a pharmaceutically acceptable salt
thereof, as an active ingredient.

10 22. A medicament comprising a pharmaceutically acceptable
excipient, at least one drug, and a compound according to
claim 1, or a pharmaceutically acceptable salt thereof, as
an active ingredient;

wherein each drug is independently selected from the
group consisting of an adrenaline beta receptor antagonist,
15 an analgesic drug, an anticonvulsant, an antidementia drug,
an antidepressant drug, an antiemetic drug, an
antiepileptic drug, an antimigraine drug, an
antiparkinsonian drug, an antischizophrenic agent, an
anxiolytic drug, a dopamine receptor agonist, a dopamine
20 supplement, a hormone preparation, a drug for treating a
mood disorder, and a sleep-inducing drug.

23. Use of the compound according to claim 1, or a
pharmaceutically acceptable salt thereof, in the
25 manufacture of a medicament for treating a central nervous
system disease or disorder or a mental disease or disorder.

24. The use according to claim 23, wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of a behavioral disorder due to psychoactive substance use, a behavioral disorder with onset usually occurring in childhood, a behavioral disorder with onset usually occurring in adolescence, a degenerative disease of the central nervous system, a delusional disorder, an emotional disorder with onset usually occurring in childhood, an emotional disorder with onset usually occurring in adolescence, an extrapyramidal movement disorder, a mental disorder due to psychoactive substance use, a mood affective disorder, a neurotic disorder, an organic mental disorder, a pervasive developmental disorder, schizophrenia, a schizotypal disorder, sexual dysfunction not caused by an organic disorder or organic disease, a sleep disorder, a somatoform disorder, and a stress-related disorder.

25. The use according to claim 24, wherein the sleep disorder is a nonorganic sleep disorder.

26. The use according to claim 23, wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, a bipolar disorder with a psychotic feature, a depressive disorder with a psychotic feature, irritation associated with Alzheimer's disease, a negative symptom of schizophrenia, a positive symptom of schizophrenia, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, a psychopathic symptom associated with

Parkinson's disease, and schizophrenia.

27. The use according to claim 26, wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

28. The use according to claim 26, wherein the psychopathic symptom associated with Parkinson's disease is a psychopathic symptom associated with Parkinson's disease with dementia.

29. The use according to claim 23, wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, irritation associated with Alzheimer's disease, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, and schizophrenia.

30. The use according to claim 29, wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

31. Use of at least one drug and the compound according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient in the manufacture of a medicament for treating a central nervous system disease or disorder or a mental disease or disorder,
wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an antiepileptic

drug, an antimigraine drug, an antiparkinsonian drug, an antischizophrenic agent, an anxiolytic drug, a dopamine receptor agonist, a dopamine supplement, a hormone preparation, a drug for treating a mood disorder, and a sleep-inducing drug.

32. The use according to claim 31, wherein first the at least one drug is to be administered to a patient, and second the compound according to claim 1, or a pharmaceutically acceptable salt thereof, is to be administered to the patient.

33. The use according to claim 31, wherein first the compound according to claim 1, or a pharmaceutically acceptable salt thereof, is to be administered to a patient, and second the at least one drug is to be administered to the patient.

34. The use according to claim 31, wherein the at least one drug and the compound according to claim 1, or a pharmaceutically acceptable salt thereof, are to be administered to a patient concurrently.

35. Use of a pharmaceutically acceptable excipient, at least one drug, and a compound according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient in the manufacture of a medicament for treating a central nervous system disease or disorder or a mental disease or disorder,

wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an antiepileptic

drug, an antimigraine drug, an antiparkinsonian drug, an
antischizophrenic agent, an anxiolytic drug, a dopamine
receptor agonist, a dopamine supplement, a hormone
preparation, a drug for treating a mood disorder, and a
sleep-inducing drug.

~~20. A medicament for treating mental disease or central
nervous system disease, comprising a compound according to
any one of claims 1 to 18, or a pharmaceutically acceptable
salt thereof, as an active ingredient.~~

~~21. The medicament according to claim 20, wherein the
mental disease or central nervous system disease is organic,
including symptomatic, mental disorders; mental and
behavioural disorders due to psychoactive substance use;
schizophrenia, schizotypal disorders, and delusional
disorders; mood [affective] disorders; neurotic disorders,
stress-related disorders, and somatoform disorders;
nonorganic sleep disorders; sexual dysfunction, not caused
by organic disorder or disease; pervasive developmental
disorders; behavioural and emotional disorders with onset
usually occurring in childhood and adolescence;
extrapyramidal and movement disorders; other degenerative
diseases of nervous system; or sleep disorders.~~

~~22. The medicament according to claim 20, wherein the
mental disease or central nervous system disease is
schizophrenia, positive symptoms of schizophrenia, negative
symptoms of schizophrenia, bipolar disorders with psychotic
features, depressive disorders with psychotic features,
psychopathic symptoms associated with dementia,
psychopathic symptoms associated with Alzheimer's disease,
psychopathic symptoms associated with dementia with Lewy~~

bodies, psychopathic symptoms associated with Parkinson's disease with dementia, psychopathic symptoms associated with Parkinson's disease, or irritation, agitation, or aggression associated with Alzheimer's disease.

5

23. The medicament according to claim 20, wherein the mental disease or central nervous system disease is schizophrenia, psychopathic symptoms associated with dementia, psychopathic symptoms associated with Alzheimer's disease, psychopathic symptoms associated with dementia with Lewy bodies, or irritation, agitation, or aggression associated with Alzheimer's disease.

24. A method for treating mental disease or central nervous system disease, comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

25. Use of a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating mental disease or central nervous system disease.

26. A compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use in the treatment of mental disease or central nervous system disease.

27. A medicament for treating mental disease or central nervous system disease, comprising a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and at least one drug selected from the group

consisting of antidepressant drugs, anxiolytic drugs, antischizophrenic agents, dopamine supplements, dopamine receptor agonists, antiparkinsonian drugs, antiepileptic drugs, analgesic drugs, hormone preparations, antimigraine drugs, adrenaline β receptor antagonists, antidementia drugs, drugs for treating mood disorders, antiemetic drugs, sleep-inducing drugs, and anticonvulsants.

28. A medicament for treating mental disease or central nervous system disease, comprising a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, as an active ingredient, for combination use with at least one drug selected from the group consisting of antidepressant drugs, anxiolytic drugs, antischizophrenic agents, dopamine supplements, dopamine receptor agonists, antiparkinsonian drugs, antiepileptic drugs, analgesic drugs, hormone preparations, antimigraine drugs, adrenaline β receptor antagonists, antidementia drugs, drugs for treating mood disorders, antiemetic drugs, sleep-inducing drugs, and anticonvulsants.